CD38: A target in relapsed/refractory acute lymphoblastic leukemia—Limitations in treatment and diagnostics. Issue 9 (20th May 2022)

• Record Type: Journal Article
• Authors: Vakrmanová, Barbora; Nováková, Michaela; Říha, Petr; Žaliová, Markéta; Froňková, Eva; Mejstříková, Ester; Starý, Jan; Hrušák, Ondřej; Šrámková, Lucie
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 9(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-05-20
• Subjects: CD38 expression -- daratumumab -- flow cytometry -- immunotherapy -- relapsed acute lymphoblastic leukemia; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29779
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Daratumumab, an anti‐CD38 antibody, is used experimentally in the treatment of relapsed acute lymphoblastic leukemia (ALL). We treated five patients suffering from relapsed ALL with daratumumab. Four patients had T ALL, three of whom achieved complete remission (CR) after treatment and underwent stem cell transplant (SCT). Two of them had a second relapse and died 6 and 8 months after SCT, respectively. One transplanted T ALL patient remained in CR2 15 months after relapse. In the remaining T‐ALL patient, the disease progressed under daratumumab treatment, and the patient died early after the first relapse. The B‐cell precursor ALL patient with a second CD19‐negative relapse, whose disease turned out to be resistant to the combination of daratumumab with chemotherapy, later achieved CR3 with inotuzumab ozogamicin, underwent SCT and remained in CR3. Leukemia burden should be monitored after daratumumab, and care should be taken not to misclassify leukemic cells with false negativity of surface CD38; using an antibody reacting with nondaratumumab epitopes is advantageous.